This is demonstrated by Wang and collaborators, who found that CXCL9 was highly expressed in patients with MASH, correlating with liver injury and complications of liver disease in humans (53). This evidence concerns the gene CXCL9 and metabolic dysfunction-associated steatohepatitis.